New York, USA - May 25, 2026 - By integrating computational design, ADMET property optimization, synthesis feasibility assessment, wet-lab validation, and pathology image analysis, the company offers a more connected and data-backed discovery workflow.
Creative Biolabs Advances AI-Driven DMTA Workflow for Drug Discovery and ADMET Optimization
